Sickle cell disease (SCD) is an umbrella term for a group of life‐long debilitating autosomal
recessive disorders that are caused by a single‐point mutation (Glu→ Val) that results in …

Sickle cell disease (SCD) is the most common life-threatening monogenic disorder in the
world. The disease is highly prevalent in malaria endemic areas with over 75% of patients …

Background Sickle cell disease (SCD) affects more than 100,000 Americans, with
complications such as pain episodes and acute chest syndrome. Despite the efficacy of …

Introduction There is a wide range of clinical manifestations in sickle cell disease (SCD).
Despite having the same condition, each person's response to disease complications differs …

Tanzania is among the top five countries with a high burden of sickle cell disease (SCD) in
the world. Even though the effects of SCD on quality of life have been documented in other …

Background Hydroxyurea (HU) is an evidence-based therapy that is currently the most
effective drug for sickle cell disease (SCD). HU is widely used in high-income countries with …

Purpose To assess clinical and haematological outcomes of Hydroxyurea accessed via
various access means and uncover the barriers to its utilization in children with Sickle cell …

The spectrum of hematological diseases in African children includes anemias, bleeding
disorders, thromboses, and oncological diseases such as leukemias. While data are limited …

Purpose Tanzania is the fifth country with the highest sickle cell disease (SCD) prevalence
globally. Although hydroxyurea (HU) is available, only 25% of persons with SCD are …

Sickle cell disease (SCD) is an inherited red blood cell disorder associated with frequent
painful events and organ damage. Hydroxyurea (HU) is the recommended evidence‐based …